Lifeward Ltd (NASDAQ: LFWD), the medical robotics company behind the ReWalk wearable exoskeleton and AlterG rehabilitation treadmills, was highlighted in a FinanceWire distribution via Investegate reference FNEWS on 17 November 2026, drawing attention to what the announcement describes as a potential valuation anomaly. The company generated $22 million in total revenue in 2025, yet carried an equity market value of approximately $11.5 million as at the 13 November 2026 close. The announcement suggests the market may be undervaluing established revenue streams, an active Medicare reimbursement pathway, and a pipeline incorporating artificial intelligence capabilities.

Key Points

  • Lifeward Ltd (NASDAQ: LFWD), covered under Investegate reference FNEWS via FinanceWire distributor FNW
  • Lifeward's total 2025 revenue was $22 million against an approximate equity market value of $11.5 million as at 13 November 2026
  • AlterG generated $12.9 million of 2025 revenue and posted 25% and 18% year-over-year growth in its two most recent quarters; ReWalk holds finalised Medicare reimbursement coverage secured in 2024
  • Investors may be watching whether new interim CEO Josh Hexter can scale distribution partnerships, including an August 2026 pilot with Ottobock Care's 50-plus US patient-care clinics

AlterG Rehabilitation Business Posts Double-Digit Growth With More Than 6,000 Systems Installed Globally

AlterG, which Lifeward acquired for approximately $19 million in 2023, uses air-pressure technology originally derived from NASA research to reduce weight-bearing load on treadmills, enabling post-surgical rehabilitation for patients including athletes recovering from knee procedures. The announcement states the business had more than 6,000 systems installed worldwide at the end of 2025, generating $12.9 million in annual revenue and supporting equipment, warranty, and service income streams. Year-over-year growth reached 25% and 18% in the two most recent quarters respectively, a trajectory the announcement highlights as being largely overlooked relative to Lifeward's $11.5 million total equity valuation.

ReWalk's Finalised Medicare Pathway and Ottobock Care Pilot Signal Distribution Rebuild Under Way

ReWalk, Lifeward's FDA-cleared wearable robotic exoskeleton for people with spinal cord injury, received initial US authorisation in 2014 and a finalised Medicare reimbursement pathway in 2024. Coverage now extends through Medicare and the three largest Medicare Advantage insurers — Aetna, Humana, and UnitedHealthcare. Management is restructuring commercial operations away from direct selling towards established provider partners. An August 2026 pilot with Ottobock Care, which operates more than 50 US patient-care clinics, and an existing distribution relationship with CorLife for workers' compensation patients, form the foundation of that strategy. Third-quarter 2026 revenue fell 12% to $5.4 million, reflecting the transitional period.

Interim CEO Josh Hexter and Oramed's 44.2% Stake Shape Lifeward's Strategic Direction

Lifeward's interim CEO Josh Hexter previously served as Chief Operating and Business Officer at Oramed Pharmaceuticals (NASDAQ: ORMP) and Chief Business Officer at BrainsWay (NASDAQ: BWAY) between 2018 and 2019. The announcement notes that Oramed has emerged as Lifeward's largest disclosed shareholder with approximately 44.2% reported ownership. Oramed separately invested $36.9 million in Alpha Tau Medical (NASDAQ: DRTS) in April 2025, implying a post-financing equity value of roughly $220 million; the announcement states Alpha Tau's equity value reached approximately $1.24 billion by 13 November 2026, a data point the article uses to contextualise Oramed's dealmaking track record.

AI-Enabled Upper-Body Exoskeleton and Connected AlterG Analytics Targeted for 2028 Launch

Lifeward's development pipeline includes a powered upper-body exoskeleton aimed at patients with arm and hand weakness following stroke, with planned AI capabilities designed to recognise intended movements and assist in completing them. The company estimates approximately 4 million Americans live with upper-limb weakness after stroke and targets a 2028 commercial launch, subject to development progress and regulatory clearance. The roadmap also encompasses connected AlterG gait analytics and an AI-enhanced next-generation ReWalk platform. The announcement notes Lifeward remains loss-making and will require continued financing, representing a material risk investors should weigh alongside the commercial opportunity.